Effect on bone turnover and BMD of low dose oral silicon as an adjunct to calcium/vitamin D3 in a randomized, placebo-controlled trial.
Completed
- Conditions
- 1. Osteopenia<br />2. orthosilicic acid<br /> 3. BMD<br /> 4. bone markers.
- Registration Number
- NL-OMON20097
- Lead Sponsor
- 1. Twin Research and Genetic Epidemiology Unit, St Thomas’ Hospital, Kings College, London, United Kingdom;<br>2. Department of Pharmaceutical Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium;<br>3. MRC Human Nutrition Research, Elsie Widdowson Laboratory, Cambridge, United Kingdom.
- Brief Summary
Journal of Bone and Mineral Research, Vol 20, Suppl 1, S172, SA 421, September 2005
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 184
Inclusion Criteria
1. Osteopenic, but otherwise healthy;
2. Caucasian women with a T-score < -1.5 at the lumbar spine by DEXA scan.
Exclusion Criteria
1. Patients were excluded according to the following criteria:
a. Renal failure as defined by serum creatinine > 200 µmol/L;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. The effect of oral choline-stabilized orthosilicic acid (ch-OSA) on markers of bone turnover and bone mineral density (BMD).
- Secondary Outcome Measures
Name Time Method 1. Ch-OSA related adverse events; <br /><br>2. Biochemical safety parameters of oral use of ch-OSA.<br>